Youth Bio Global
Youth Bio Global was established in August 2017 with the purpose of providing universal medical services to patients suffering from rare and incurable diseases. We aim to become a leading global healthcare provider that contributes to improving human health and quality of life based on cutting-edge diagnostic and treatment technologies.
Management team
Founder & CEO: JUSTIN (SEUNG HO) YOO / Chief Technology Officer: SANG MO, BAE (Plastic Surgeon/Ph.D)
Seung Ho (Justin) Yoo holds a Ph.D. (Medicine) and an MPH from Seoul National University. With a diverse career spanning various prestigious roles, including serving as an evaluator of the Advanced Regenerative Medicine Clinical Research Support Project and an Adjunct Professor at Dongguk University’s Biomedical Engineering Department since 2017. Additionally, he has been involved in multiple associations and committees related to healthcare and regulatory affairs. Dr. Yoo has received numerous awards for his contributions to the field, including recognition from government agencies and healthcare institutions. Moreover, he holds over 10 patents and has authored or co-authored over 10 papers/abstracts.
Financing
- Total Investment: US$5 million (Including Grants)
- Common Stock: 100% (as of Jul.’24)
- CEO has about 76% of Stock
- Angel investors ONLY
Seeking first VC investment
- Round: Series A (Pre A)
- Fund Raising: A bout US$3-5 million
- Valuation: About US$20 million
Use of funds
- 65% product development (CMO & Clinical)
- 11% Marketing/Sales
- 20% Operation/Inventory
- 2% Existing debt, 2% Legal/Other
Patents
More than 30+ patents registered or applied.
The business
Short-term advantages include diversification of business by expanding into various ischemic diseases such as myocardial infarction, stroke, and retinopathy, starting with the development of vascular stem cell therapies targeting the diabetic foot indication (designated as a fast track).
The company plans to target the total wound care and vascular stem cell market through the sale of stem cell culture medium and wound dressings based on their patented technology. Then, they plan to expand their business and increase their market share by developing and conducting clinical trials, obtaining product approvals, and licensing out for some indications. Based on this excellent vascular stem cell technology, they expect to accelerate their growth rate by conducting R&D with high expandability, such as stem cell therapies and combination products, etc.
Financial performance
Projections
| ‘24 | ‘25 | ‘26 | ‘27 | ‘28 | ‘29 |
| REVENUE $0.6M | $1M | $2M | $7M | $11M | $15M |
| GRANTS $1M | $2M | $1.5M | $1.2M | $2M | $2.2M |
| EBITDA ($0.8M) | ($1.2M) | ($0.6M) | $2.1M | $3.2M | $4.5M |
- For more information, visit: www.linkedin.com/company/youth-bio-global
